All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What treatment would you suggest for high risk MDS patients not fit for chemotherapy or hematopoietic stem cell transplantation (HSCT)?
What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?
Brunner discusses the challenges associated with treatment for patients who are not fit for chemotherapy or HSCT. He goes on to discuss hypomethylating agent therapy, such as azacitidine and decitabine regimens, as well as talking about supportive care.
Subscribe to get the best content related to MDS delivered to your inbox